Faster and more efficient

Rapid progress has been made in genomics and proteomics research in recent years. This has opened up new perspectives for medical diagnosis and treatment of cancer. ABCSG aims to make effective use of these new insights. To do this, it intends to establish a Central Research Facility to lead the fight against breast cancer and colorectal cancer – with greater speed and efficiency than ever before.

Collecting and analysing tissue

Tumour tissue contains vital information on genetic and other molecular changes inside the tumour that originally caused the cancer to develop. Using the latest methods of molecular biology and biochemistry, we could decrypt this information and use it for cancer research. This requires a Central Research Facility to be created, where tumours and healthy tissue can be stored and compared.

New in Austria

ABCSG has conducted clinical trials over a period of many years. As a result, it has access to a large amount of detailed patient data. This provides an excellent basis for our research, and increases the scientific value of a Central Research Facility. A combination of this nature is entirely unprecedented in Austria.


ABCSG must make tumour patients aware in advance that they will not suffer any harm by giving consent for their tumour tissue to be stored in a Central Research Facility. In fact, by giving their consent, they will be making a significant contribution to the development of new methods of diagnosis and treatment. The Ethics Committee will serve as the official supervisory body, as is the case for all clinical trials conducted by ABCSG.


abcsg.research was filed at the Ethics Commission as a translational research project, under the project title of ‘Prediction of response or resistance of tumours to therapy with anti-hormonal substances and/or chemotherapy with taxanes’. The project involved non-therapeutic biomedical research involving human subjects (basic research). The project application has been approved by the Ethics Committee. The application included the scientific protocol and patient information/consent form, and the requirement for sampling of tissue. This submission is updated annually by the trial coordination centre at ABCSG.

Treatment response

The characterization of new prognostic parameters, the development of new therapeutic approaches, and the prediction of how patients will respond to different therapies are within reach for the first time, leading step by step to the individualization of tumor therapy.


The necessary logistics as well as the support for pathologists is provided within the ABCSG project. Additional information such as disease progression, treatment, family history and laboratory data ultimately vastly increase the scientific efficiency of biospecimen collection. It is precisely these data that an Austria-wide study group such as the ABCSG has at its disposal.


The biological samples are collected in strict compliance with applicable laws and data protection. They are processed in the ABCSG Central Research Facility in compliance with Good Laboratory Practice (GLP) and applicable project approvals and used scientifically in accordance with the cooperative leitmotif of the study group.

Share on